NorthStar Medical Radioisotopes, LLC, a global provider of radiopharmaceuticals used to detect and treat cancer and other serious diseases, has signed a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials. The overarching Master Service agreement and associated Clinical Supply Agreement are effective immediately and the initial production of supply to support Clarity trials is expected to occur before the end of 2024.
Clarity Pharmaceuticals is moving to the assessment of a second patient cohort for its Phase I/II theranostic trial, SECuRE.
Clarity Pharmaceuticals has dosed the first participant in the therapeutic phase of its Phase I/II theranostic trial of 64Cu/67Cu SAR-bisPSMA theranostic products for metastatic, castrate-resistant prostate cancer (mCRPC) treatment.